Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
2023年7月12日 - 6:00AM
Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage
biopharmaceutical company focused on developing drugs that
meaningfully improve the lives of patients with rare
cardiopulmonary disease, today announced the appointment of Habib
Dable as a member of Aerovate’s Board of Directors. Mr. Dable is
the former President and Chief Executive Officer of Acceleron
Pharma Inc. and brings nearly three decades of experience working
with emerging biotech and big pharma companies.
"We are excited to welcome Habib to Aerovate’s Board of
Directors. Habib’s deep experience in leading both big pharma and
emerging biotech companies will be incredibly valuable as we
continue advancing AV-101, our novel dry powder inhaled formulation
of the drug imatinib, for the treatment of pulmonary arterial
hypertension, also known as PAH, through clinical development,”
said Timothy Noyes, Chief Executive Officer of Aerovate.
Mr. Dable currently serves as a member of the Boards of
Directors of Blueprint Medicines Corporation and PepGen Inc., and
also served as a member of the Boards of Directors of Albiero
Pharm, Inc. and Millendo Therapeutics Inc. As President and Chief
Executive Officer of Acceleron Pharma Inc., Mr. Dable guided
Acceleron to its first blockbuster launch in 2019 and eventual sale
to Merck & Co. in 2021 for over $11 billion. Prior to his role
at Acceleron, Mr. Dable worked at Bayer AG where, over the course
of his 22-year tenure, he served in roles of increasing
responsibility, including Global Head, Neurology and Ophthalmology
and President of U.S. Pharmaceuticals. During this time, Mr. Dable
led the launch of various brands, including EYLEA®, Stivarga®, and
Xofigo®. Mr. Dable is currently a part-time Venture Partner at RA
Capital Management, L.P., and previously served on the Board of
Directors of the Biotechnology Innovation Organization (BIO).
“The appointment of Mr. Dable further enhances the diverse
expertise of our Board as Aerovate continues to advance AV-101
through the clinic,” said Mark Iwicki, Chair of the Board. “We look
forward to having Habib on the Board as we support the company’s
ongoing growth.”
“I am honored to join the Board during a pivotal time for the
company,” said Mr. Dable. “Having previously worked in the PAH
space, I have seen the impact of PAH on patients and the unmet need
for meaningful treatment options. I am encouraged to see the next
generation of PAH therapies advance in clinical development,
including Aerovate’s novel AV-101.”
About Aerovate Therapeutics, Inc.Aerovate is a
clinical-stage biopharmaceutical company focused on developing
drugs that meaningfully improve the lives of patients with rare
cardiopulmonary disease. Aerovate's initial focus is on advancing
AV-101, its proprietary dry powder inhaled formulation of the drug
imatinib for the treatment of patients with PAH. Learn more at
aerovatetx.com and follow the company on Twitter and LinkedIn.
Available InformationAerovate
announces material information to the public about the Company, its
products and services, and other matters through a variety of
means, including filings with the U.S. Securities and Exchange
Commission (SEC), press releases, public conference calls,
webcasts, the investor relations section of the Company website at
ir.aerovatetx.com, and the Company’s Twitter account @AerovateTx in
order to achieve broad, non-exclusionary distribution of
information to the public and for complying with its disclosure
obligations under Regulation FD.
Cautionary Note Regarding
Forward-Looking StatementsThis press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements can be identified by words such as
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“future,” “goal,” “intend,” “look forward to,” “may,” “plan,”
“potential,” “predict,” “project,” seek,” “strategy,” “should,”
“target,” “will,” “would” and similar expressions regarding future
periods. These forward-looking statements include, but are not
limited to, statements regarding the therapeutic potential and
clinical benefits of AV-101; our business plans and objectives for
AV-101, including expectations regarding timing and success; and
our growth and goals as a company.
Any forward-looking statements in this press
release are based on management’s current expectations and beliefs
and are subject to a number of risks, uncertainties and important
factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, those risks and uncertainties related to the
therapeutic potential of AV-101; the expected impact and
contribution of our Board of Directors and executives to our
business; as well as those risks and uncertainties set forth more
fully under the caption “Risk Factors” in our most recent Annual
Report on Form 10-K filed with the SEC and subsequent filings with
the SEC. We caution you not to place undue reliance on any
forward-looking statements, which speak only as of the date they
are made. We disclaim any obligation to publicly update or revise
any such statements to reflect any change in expectations or in
events, conditions or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.
Any forward-looking statements contained in this press release
represent our views only as of the date hereof and should not be
relied upon as representing its views as of any subsequent
date.
Media Contactinfo@aerovatetx.com
Investor Contactir@aerovatetx.com
Aerovate Therapeutics (NASDAQ:AVTE)
過去 株価チャート
から 4 2024 まで 5 2024
Aerovate Therapeutics (NASDAQ:AVTE)
過去 株価チャート
から 5 2023 まで 5 2024